|
| |
The Immune Response CorporationThe Immune Response Corporation (OTCBB: IMNR.OB) is an immuno-pharmaceutical company focused on developing products to treat autoimmune and infectious diseases. The Company’s lead immune-based therapeutic product candidates are NeuroVax™ for the treatment of MS and IR103 for the treatment of HIV infection. Both of these therapies are in Phase II clinical development and are designed to stimulate pathogen-specific immune responses aimed at slowing or halting the rate of disease progression.
NeuroVax™, which is based on the Company’s patented T-cell receptor (TCR) peptide technology, has shown potential clinical value in the treatment of relapsing forms of MS. NeuroVax™ has been shown to stimulate strong, disease-specific cell-mediated immunity in nearly all patients treated and appears to work by enhancing levels of FOXP3+ Treg cells that are able to down-regulate the activity of pathogenic T-cells that cause MS. Increasing scientific findings have associated diminished levels of FOXP3+ Treg cell responses with the pathogenesis and progression of MS and other autoimmune diseases such as rheumatoid arthritis (RA), psoriasis and Crohn’s disease. In addition to MS, the Company has open Investigational New Drug Applications (IND) with the FDA for clinical evaluation of TCR peptide-based immune-based therapies for RA and psoriasis
| Contact Details: |
| 5931 Darwin Court |
| Carlsbad |
| California |
| 92008 |
| United States of America |
| Tel: | 760-431-7080 |
| Fax: | 760-431-8636 |
| Email: | |
| WWW: | www.imnr.com/
|
|
Loading...
|
Recent Publications by The Immune Response Corporation: |  |
Identification of reciprocally regulated gene modules in regenerating dorsal root ganglion neurons and activated peripheral or central nervous system glia.
Differential gene expression in the rat after injury of dorsal root... | 3rd December, 2003
| The Immune Response Corporation, 5935 Darwin Court, Carlsbad, California
| J Cell Biochem. 2003 Apr 1;88(5):970-85.
DOI Direct Link |
HIV-specific immunity during structured antiviral drug treatment interruption.
The immunologic correlates associated with control of viremia in HIV... | 1st November, 2003
| The Immune Response Corporation, 5935 Darwin Court, Carlsbad, CA 92008,
| Vaccine. 2003 Mar 7;21(11-12):1066-71.
|
Propofol phosphate, a water-soluble propofol prodrug: in vivo evaluation.
After a single IV injection of the water-soluble propofol prodrug propofol... | 26th November, 2002
| Chemistry Department, The Immune Response Corporation, 5935 Darwin Court,
| Anesth Analg. 2002 Nov;95(5):1285-92, table of contents.
|
Novel membrane-bound GM-CSF vaccines for the treatment of cancer: generation and evaluation of mbGM-CSF mouse B16F10 melanoma cell vaccine.
Cancer vaccines composed of tumor cells engineered to secrete... | 18th October, 2002
| Division of Cancer, The Immune Response Corporation, 5935 Darwin Court,
| Gene Ther. 2002 Oct;9(19):1302-11.
DOI Direct Link |
Maternal and newborn immunization with a human immunodeficiency virus-1 immunogen in a rodent model.
We examined immunization with an inactivated, gp120-depleted human... | 3rd October, 2002
| The Immune Response Corporation, Carlsbad, California 92008, USA.
| Immunology. 2002 Aug;106(4):549-53.
|
→View more The Immune Response Corporation research publications. |
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 512 times since April 2007, the link to the organisation's website has been followed 104 times Recent Search Terms used to find this page: crohn panenza | immune response corporation 2009 | ms immune response | immune response corporation | . Search for more companies in Carlsbad Search for more companies in California This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for The Immune Response Corporation |
